<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-BFTJLIQE</identifier><date>2009</date><creator>Kos, Janko</creator><relation>documents/znanstveni_clanki/farmacevtski_vestnik/html/URN_NBN_SI_doc-BFTJLIQE.html</relation><relation>documents/znanstveni_clanki/farmacevtski_vestnik/pdf/URN_NBN_SI_doc-BFTJLIQE.pdf</relation><relation>documents/znanstveni_clanki/farmacevtski_vestnik/txt/URN_NBN_SI_doc-BFTJLIQE.txt</relation><format format_type="issue">2</format><format format_type="main">6 strani</format><format format_type="volume">60</format><format format_type="type">article</format><format format_type="extent">str. 61-66</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">24148007</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-BFTJLIQE</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">biološka zdravila</subject><subject language_type_id="slv">onkologija</subject><subject language_type_id="slv">rak (medicina)</subject><title>Biological drugs</title><title>Biološka zdravila proti raku</title></Record>